Cholesterol breakthrough and HDL therapy

AHA   Where there any breakthroughs at the AHA meeting in Chicago

Answer: 

Yes, a novel Cholesterol treatment is a rising star called anacetrapib

<!-- article-content -->

  members circle Raising good cholesterol to a significant degree can presently only be accomplished with Niacin or exercise. HDL acts as a key dump truck in our body, taking cholesterol from the circulation to the liver where it can be made into useful products or removed. 

A new era in cholesterol treatment may have dawned at the American Heart Association Meeting in Chicago. From the Late Breaking Clinical Trials session on the last day of the meeting, a Cholesteryl Ester Transfer Protein inhibitor known as anacetrapib was found to avoid the problems of a prior attempt in this family (torcetrapib) and the presenters resoundingly recommended that further studies commence!

I expect that the FDA will give this new drug fast track status (see www.fda.gov) and a brand new family of medicines will be born. The old target was bad cholesterol (LDL) and the new mantra will be LDL lowering and HDL raising combination therapy!

 

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.